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Abstract. Acute Chagas disease is rarely recognized, and the risk for acquiring the disease is undefined in travelers to
Central America. We describe a case of acute Chagas disease in a traveler to Costa Rica and highlight the need for
increased awareness of this infection in travelers to Chagas-endemic areas.
INTRODUCTION
Acute Chagas disease, caused by infection with the para-
site Trypanosoma cruzi, is a rarely recognized condition,
even in areas where ongoing transmission is endemic. In the
United States, seven cases of acute Chagas disease associated
with vector-borne transmission have been reported since
19551–8; all cases were domestically acquired, and none of
the cases were identified in returning travelers. We discuss
the presentation of a patient returning from a brief vacation
in Costa Rica with symptoms of acute Chagas disease.
CASE REPORT
A 53-year-old Caucasian female with no significant past
medical history presented to the local emergency department
in May of 2008 with complaints of fever, headaches, and left
eye swelling 2 weeks after returning from a 3-week trip to
Puerto Viejo, Costa Rica (Limon province). The patient and
her husband visited a small village, where they slept on a bed
net-covered wooden platform bed in a one-room cottage that
lacked netted windows and doors.
The patient had an uneventful stay in Costa Rica, and her
symptoms developed 2 days after her return. Her initial symp-
toms included left eye swelling, pruritis, and pain. These
symptoms progressed rapidly over the next few days until the
patient’s left eye was swollen shut, prompting a referral to an
ophthalmologist. The patient was subsequently treated for
allergic reaction and blepharoconjunctivitis. After no initial
response to antimicrobials (levofloxacin, doxycycline, and
tobramycin eye drops) and the development of fevers as high
as 102.9°C, the patient was sent to the emergency department
to be evaluated for periorbital cellulitis. She complained of
left eye pain, headaches, daily fevers to 102°C, dyspnea on
exertion, decreased energy, decreased appetite, and a blotchy
rash most noticeable after a shower. She denied chest pain,
palpitations, lower extremity edema, emesis, diarrhea, dys-
phagia, or odynophagia.
On physical examination, temperature was normal at
37.1°C, heart rate was 91 beats/min, blood pressure was 98/
62 mmHg, respiratory rate was 18 breaths/min, and oxygen
saturation was 98% on room air. She did not appear to be in
any distress. There was periorbital edema and mild erythema
of the left eye, with pronounced orbital rim edema (Figure 1).
There was no visible discharge from the left eye. The right eye
was normal. Her pupils were equal, round, and reactive to light.
Extraocular movements were intact with two beats of lateral
gaze nystagmus. Her sclerae were anicteric, and conjunctivae
were pink without injection. Her oropharynx was clear without
evidence of erythema, thrush, or exudate. She had one small
non-tender, freely mobile right posterior cervical lymph node,
and otherwise, she had no significant lymphadenopathy. Car-
diovascular, pulmonary, and abdominal examinations were
normal. The skin showed diffuse patches of macular, mildly
erythematous, non-blanching lesions that were non-pruritic.
Physical examination was otherwise unremarkable.
Laboratory tests revealed a white blood cell count of
6,100 cells/mL, hemoglobin of 11.8 g/dL, and platelet count of
222,000 cells/mL. The white blood cell differential notes an
absolute neutrophil count of 3.8 + 109/L, absolute lympho-
cyte count of 1.7, absolute monocyte count of 0.1 (low), abso-
lute eosinophil count of 0.0, and absolute basophil count of
0.0. The peripheral blood smear revealed the presence of
atypical lymphocytes and an increase in large undifferentiated
cells (LUCs) to 7% (normal = 0–4%). Urinalysis did not show
abnormalities. Chemistry panel was normal, with a creatinine
of 0.6 mg/dL. Liver function testing was notable for transami-
nases at the upper limit of normal (aspartate aminotransfer-
ase [AST] = 53 U/L, alanine aminotransferase [ALT] = 48
U/L). Blood cultures were negative. A surface swab of the left
eye was sent for culture and grew normal skin flora; 12-lead
echocardiogram (EKG) revealed normal sinus rhythm but
with a low voltage QRS complex. In response to this finding,
a transthoracic echocardiogram (TTE) was performed, show-
ing a normal left ventricular ejection fraction (60%), but it
noted abnormalities, including diastolic left ventricular dys-
function, elevated left ventricular filling pressure, dilated left
atrium, thickened pericardium, and a small circumferential
pericardial effusion. Peripheral blood smear showed trypo-
mastigotes of T. cruzi. This finding was confirmed by the
Centers for Disease Control and Prevention (CDC), Parasitic
Diseases Branch.
In collaboration with the CDC, the patient’s blood was
tested with multitarget polymerase chain reaction (PCR; pos-
itive), enzyme-linked immunosorbent assay (ELISA; posi-
tive, optical density [OD] = 2.4), and indirect fluorescent
antibody (IFA) testing (positive, titer 1:64). Hemoculture
was negative from initial blood samples, although this result
may reflect the difficulty of culturing this parasite or samples
for culture that were not in optimal condition. The patient
was quickly initiated on nifurtimox therapy, which was the
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only treatment drug for Chagas disease available at CDC
under a compassionate use protocol (8 mg/kg per day) at that
time; treatment continued for 90 days. The patient’s therapy
was complicated by side effects, including aguesia, anorexia,
decreased energy, insomnia, irritability, difficulty with mem-
ory, moderate depression and anxiety, and transient throm-
bocytopenia and transaminitis. Follow-up TTEs and EKGs
normalized during the course of therapy. Neuropsychiatric
side effects dissipated slowly after the completion of a full
course of therapy. Peripheral smear was negative for the
parasite at week 1 after treatment initiation. The PCR
remained positive until 4 weeks of treatment were com-
pleted, and it became negative after 2 months of treatment.
The IFA remained positive (1:64) at 13 months of follow-up.
The patient continues follow-up with a primary care pro-
vider. The patient’s husband was also tested for evidence of
T. cruzi infection 22 days after returning from Costa Rica.
Testing by PCR, hemoculture, and serology yielded negative
results. The Costa Rican Ministry of Health was notified of
the case of acute Chagas disease in this traveler.
DISCUSSION
Chagas disease predominantly affects persons indigenous
to Latin America. Chagas disease is transmitted most fre-
quently through the triatomine vector. However, congenital,
blood-borne, organ-derived, and oral transmissions also
occur. Chagas disease in the United States has been recently
reviewed, with discussion of T. cruzi’s life cycle, transmission,
clinical manifestations, and diagnosis discussed in detail.9
Importantly, because of migration, Chagas disease is a prob-
lem of increasing concern in North America and Europe
because of the sequelae of long-term infection in individual
patients and protection of blood supplies against contamina-
tion with parasites.
Figure 1. (A and B) Patient presented clinical findings of Romaña’s sign. (C) Patient’s initial smear contained trypanosomes (Diff Quick;
1,000 + magnification). (D) Hut that the patient was residing in at the time of exposure. (E) Location of Puerto Viejo within Limon Province
(highlighted in red).13
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Acute Chagas disease is often unreported because of the
lack of readily identifiable clinical symptoms, and the occur-
rence of acute infection among short-term travelers is likely
greater than reported occurrence. Acute disease usually occurs
in children in populations where vector-borne transmission is
endemic, but acute infection can occur at any age. Symptoms
are generally mild or suggest a non-specific febrile illness. Ini-
tial symptoms of disease may occur between 1 and 4 weeks
after infection. Severe acute disease is rare and may include
acute myocarditis or meningoencephalitis. Chagomas are indu-
rated areas of erythema and swelling at the site of parasite
penetration. Romaña’s sign is the classic sign of acute Chagas
disease, and it is characterized by painless edema of the
palpebrae and periocular tissues that appear when the conjunc-
tiva was the parasite’s route of entry; however, not all patients
with acute Chagas disease present with Romaña’s sign. Patients
with orally transmitted acute Chagas disease have more severe
symptoms of infection. A case series of 13 patients with orally
acquired acute Chagas disease in Brazil showed the following
clinical manifestations in greater than 30% of cases: fever,
dyspnea, myalgia, periorbital edema, headache, cardiac mur-
mur, nausea, cough, abdominal pain, hepatomegaly, thoracic
pain, and emesis.10
Reported acute Chagas disease in travelers is an extremely
rare occurrence. Previously, the GeoSentinel Surveillance
Newsletter described a case of travel-related acute Chagas
disease in a Canadian woman who had spent 5 months in rural
southern Mexico in June of 2008.11 Our case is unique in that
transmission occurred in a short-term traveler who would be
considered at relatively low risk of disease acquisition, and it
occurred in a region not typically associated with a high inci-
dence of disease.
Chagas disease transmission has been reported in Costa
Rica as early as 1941, but current information on incidence in
Costa Rica is lacking. Costa Rica has emerged as a major
tourist destination for ecotourism over the past several decades.
Tourism numbers have increased from 329,000 arrivals in 1988
to 2,100,000 arrivals in 2010.12 Tourists from North America
and European countries made up 61% of all international vis-
itors to Costa Rica. Travelers should be educated concerning
risks for vector-borne disease transmission, including Chagas
disease, and preventive measures during pre-travel counseling.
This case highlights the need for heightened awareness of
acute Chagas disease as a cause of acute febrile illness in
short-term travelers to endemic areas, especially because the
clinical syndrome may be subtle. As numbers of international
tourists and tourists engaging in activities that potentially
place them in contact with vectors continue to increase, there
is potential for similar cases. Travelers to Chagas disease-
endemic areas should be advised to avoid residence in poorly
constructed dwellings, sleep under insecticide-impregnated
bed nets, and tuck in the edges to provide a physical barrier
to the triatomine bugs. Travelers should also be advised
to take precautions while engaging in outdoor activities.
Consultations about diagnosis and treatment of suspected
Chagas disease can be directed to the Division of Parasitic
Diseases and Malaria, CDC (phone: 404-718-4745; E-mail:
parasites@cdc.gov; CDC emergency operator [after business
hours and on weekends]: 770-488-7100). Infectious disease spe-
cialists, emergency room physicians, primary care physicians,
and travel clinic physicians should be alert to the possibility of
acute Chagas disease in travelers returning from endemic areas
of Latin America.
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